The follow-up for that study was only a median of 60 days. However, that study also suggested that current users of ADHD medication had less occurrence of the composite of MI, sudden cardiac death, and stroke compared with nonusers.Īnother study that looked at methylphenidate found a greater risk for sudden cardiac death or ventricular arrhythmia and all-cause mortality in users versus nonusers. Overall, CV risk was not increased, but there was a trend toward more adverse CVD events in patients who had recently started taking ADHD medications. The largest study in adults included more than 400,000 people ages 25 to 64 years who had a median duration of use of ADHD medications of 4 months and a median follow-up of 1.3 years. We need to track this closely and we need to be really careful about doses, about who's getting it, and how long they're taking it. That’s a problem, Torres-Acosta and colleagues say, because longer follow-up may be required to fully grasp the CV risks of the various medications. At 9.5 years, that study’s follow-up is far longer than most of the stimulant data. But other data, including a large Danish study of over 1.2 million people ages 2 to 24 years, found no heightened risk of MI, sudden cardiac death, or stroke. These included arrythmias, increased emergency department visits for cardiac complaints, and even sporadic cases of sudden cardiac death in children. In a review of the literature looking at potential cardiovascular toxicity of pharmacotherapies including amphetamine salts, methylphenidate, lisdexamfetamine, atomoxetine, and methamphetamine, O’Keefe and colleagues led by Noel Torres-Acosta, MD (University of Missouri-Kansas City), found a mixed bag of reported CV events in kids and adults alike. “We need to track this closely and we need to be really careful about doses, about who's getting it, and how long they're taking it.” O’Keefe, MD (Saint Luke’s Mid America Heart Institute, Kansas City, MO). “It's a public health message that I think is overdue,” said James H. While there are upsides for many users, such as better concentration in school or work, they are not benign therapies. In an interview with TCTMD, a co-author said US physicians and the general public have been “too lackadaisical” about prescription stimulant medications. Researchers say prescribing rates of the medications have been climbing in the United States while global rates of ADHD remain relatively stable. Despite evidence that prescription stimulants used to treat attention-deficit/hyperactivity disorder (ADHD) raise blood pressure and resting heart rate, the literature is unclear with regard to the long-term CV risks of using them, according to a review paper.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |